menu
    • menu
    [{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mankind Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Posaconazole","moa":"CYP51A1","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gastro-Resistant Tablet","sponsorNew":"Mankind Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"MKP10241","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Mankind Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mankind Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mankind Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Molnupiravir","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mankind Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Formoterol Fumarate","moa":"ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mankind Pharma \/ Mankind Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Pharma \/ Mankind Pharma"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Panacea Biotec Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Approved","graph3":"Mankind Pharma","amount2":0.25,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.25,"dosageForm":"Capsule","sponsorNew":"Mankind Pharma \/ Panacea Biotec","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Pharma \/ Panacea Biotec"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Actimed Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Pindolol","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Mankind Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"Mankind Pharma \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Mankind Pharma \/ Mankind Pharma"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Actimed Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Series A Financing","leadProduct":"S-pindolol Benzoate","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Mankind Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"","sponsorNew":"Mankind Pharma \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Mankind Pharma \/ Mankind Pharma"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Budesonide","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol (PMDI)","sponsorNew":"Mankind Pharma \/ Mankind Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Pharma \/ Mankind Pharma"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Bharat Serums & Vaccines ltd","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDIA","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Carboprost Tromethamine","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Mankind Pharma","amount2":1.6399999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Mankind Pharma \/ Mankind Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Pharma \/ Mankind Pharma"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Vonoprazan Fumarate","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Mankind Pharma \/ Mankind Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Pharma \/ Mankind Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Mankind Pharma

    Menu

    Mankind Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Carboprost Tromethamine

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Discovery

                            Recipient : Bharat Serums & Vaccines ltd

                            Deal Size : $1,640.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            India's Mankind Pharma to Buy Bharat Serums in a $1.6 Billion Deal

                            Details : Through the acquisition of BSV, Mankind will enhance its pipelines including Endoprost (Carboprost Tromethamine), which is indicated for the treatment of post partum haemorrhage.

                            Brand Name : Endoprost

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 25, 2024

                            Lead Product(s) : Carboprost Tromethamine

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Discovery

                            Recipient : Bharat Serums & Vaccines ltd

                            Deal Size : $1,640.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vonoprazan Fumarate

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Recipient : Takeda Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India

                            Details : Under the terms of this agreement, Takeda has granted Mankind Pharma non-exclusive patent licensing rights for the commercialization of Voquezna (vonoprazan) in India.

                            Brand Name : Voquezna

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : Vonoprazan Fumarate

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Recipient : Takeda Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Budesonide,Formoterol Fumarate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Recipient : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Mankind Pharma Enters Exclusive Pact to Distribute AstraZeneca's Symbicort in India

                            Details : Under the agreement, Mankind Pharma will distribute AstraZeneca's anti-asthma inhaled corticosteroid drug Symbicort, (budesonide/formoterol) approved to treat asthma and COPD, in India.

                            Brand Name : Symbicort

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 13, 2024

                            Lead Product(s) : Budesonide,Formoterol Fumarate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Recipient : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S-pindolol Benzoate

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Recipient : Actimed Therapeutics

                            Deal Size : $6.3 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Actimed Therapeutics Closes Over-Subscribed Series A Financing Round of £5 Million to Advance Clinical Develo...

                            Details : The investment will support the development of the Actimed pipeline, including ACM-001.1 (S-pindolol benzoate), with preparations under way for a Phase 2b/3 programme targeted at the treatment of cancer cachexia in non-small cell lung cancer and colorect...

                            Brand Name : ACM-001.1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 26, 2023

                            Lead Product(s) : S-pindolol Benzoate

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Recipient : Actimed Therapeutics

                            Deal Size : $6.3 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pindolol

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Recipient : Actimed Therapeutics

                            Deal Size : $12.1 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Actimed Therapeutics Successfully Closes Second Tranche Of £10m Seed Financing To Progress Pipeline For Treat...

                            Details : ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients.

                            Brand Name : ACM-001.1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 04, 2023

                            Lead Product(s) : Pindolol

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Recipient : Actimed Therapeutics

                            Deal Size : $12.1 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Formoterol Fumarate,Fluticasone Propionate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Recipient : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Mankind Pharma to Acquire Combihale and Daffy Brands From Dr Reddy's Laboratories

                            Details : The acquisition of “Combihale” is expected to strengthen Mankind’s presence in the inhalation respiratory market segment. Daffy is a soap-free moisturising bar for infant babies.

                            Brand Name : Combihale

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 16, 2022

                            Lead Product(s) : Formoterol Fumarate,Fluticasone Propionate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Recipient : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Panacea Biotec Limited

                            Deal Size : $251.1 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Panacea Biotec Sells Domestic Formulation Assets To Mankind Pharma for Rs 1,908 Crore

                            Details : The top selling brands are Pangraf (tacrolimus), Alphadol (alfacalcidol), Cilamin (penicillamine) & Livoluk Fibre (lactulose in combination with ispaghula) were ranked number 1, whereas Glizid (Gliclazide + Metformin), Mycept (Mycophenolate Mofetil) were...

                            Brand Name : Pangraf

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 01, 2022

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Panacea Biotec Limited

                            Deal Size : $251.1 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Molnupiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mankind Pharma to Launch Cheapest Covid Antiviral Drug Molnupiravir at Rs 35 Per Capsule by Next Week : Report

                            Details : Mankind pharma launched Molulife (Molnupiravir) developed by MSD and Ridgeback Biotherapeutics by next week, It is also expected that Cipla, Sun pharma, and DRL will also release Molnupiravir in the coming weeks for the treatment of patients with severe ...

                            Brand Name : Molulife

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 05, 2022

                            Lead Product(s) : Molnupiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mankind Pharma Launches Justoza to Treat Diabetes, Heart Failure & CKD

                            Details : Mankind Pharma has launched Justoza, a Dapagliflozin brand marketed by Mankind to treat diabetes, heart failure and chronic kidney disease. Launching API DMF grade dapagliflozin is an innovative futuristic approach to provide the best in class quality to...

                            Brand Name : Justoza

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 22, 2021

                            Lead Product(s) : Dapagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Mankind Pharma

                            India arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MKP10241

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mankind Pharma Gets CDSCO Panel Nod for Phase I Trial of Anti-Diabetic Drug, MKP10241

                            Details : MKP10241, a new class of anti-diabetic molecules, is designed and developed at the Mankind Research Centre. It is a potent and orally administered small molecule, GPR119 agonist. GPR 119 is highly expressed in pancreatic beta cells and intestinal enteroe...

                            Brand Name : MKP10241

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 19, 2021

                            Lead Product(s) : MKP10241

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth